However, whether the tumor cell-intrinsic transcriptional enhancers, in particular, MLL3 and MLL4-regulated enhancers, are involved in tumor immune response and therapeutic resistance to checkpoint blockades remain incompletely understood. This evidence concerns the gene KMT2D and neoplasm.